Good afternoon :)
Place Order
Add to Watchlist

Suven Life Sciences Ltd

SUVEN

Suven Life Sciences Ltd

SUVEN
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,829 cr, stock is ranked 987
High RiskStock is 3.66x as volatile as Nifty
134.903.95% (+5.13)
134.903.95% (+5.13)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,829 cr, stock is ranked 987
High RiskStock is 3.66x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Low

Profitability and efficiency haven't been upto the mark

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,829 cr, stock is ranked 987
High RiskStock is 3.66x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-19.3810.48—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.116.510.52%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Suven Life Sciences Limited is a bio-pharmaceutical company, engaged in the business of manufacture and sale of bulk drugs and intermediaries.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of -33.64%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.14% to 0.01%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue518.81564.62648.53312.9228.4521.2317.1627.9940.2826.81
Raw Materialssubtract178.45154.81176.1679.620.000.000.000.000.00167.63
Power & Fuel Costsubtract29.3231.5033.5619.371.630.000.000.000.26
Employee Costsubtract40.9452.1761.2736.4917.4118.5321.0218.6218.99
Selling & Administrative Expensessubtract113.67124.44117.18136.02107.8873.85109.14118.13117.48
Operating & Other expensessubtract35.4851.5438.8928.563.211.043.932.552.83
Depreciation/Amortizationsubtract17.5021.4121.3110.794.174.354.396.546.506.06
Interest & Other Itemssubtract5.885.684.631.910.550.940.670.410.300.11
Taxes & Other Itemssubtract25.7335.8871.8424.06-12.18-5.320.000.00-1.00-1.00
EPS0.260.320.45-0.09-0.65-5.22-8.25-6.29-4.82-6.69
DPS0.090.050.070.070.000.000.000.000.000.00
Payout ratio0.350.150.15—0.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2018

Annual report

PDF

Investor Presentation

May 15PDF
Jan 30PDF
Nov 11PDF
FY 2019

Annual report

PDF

Investor Presentation

May 25PDF
Feb 5PDF
Feb 5PDF
+2 more
FY 2020

Annual report

PDF

Investor Presentation

Nov 14PDF
Aug 14PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Suven Life Sciences Ltd-26.9310.48—
Sun Pharmaceutical Industries Ltd44.626.370.76%
Cipla Ltd30.064.620.85%
Torrent Pharmaceuticals Ltd67.9216.410.84%

Price Comparison

Compare SUVEN with any stock or ETF
Compare SUVEN with any stock or ETF
SUVEN
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding70.27%1.05%0.00%0.34%28.34%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.47%0.50%0.54%0.46%0.45%0.34%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 3 Mutual Funds holding Suven Life Sciences Ltd




Funds (Top 3)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Quant Business Cycle Fund - Growth - Direct Plan

Growth
0.6437%1.18%-0.20%25/43 (-8)
Quant Healthcare Fund - Growth - Direct Plan

Growth
0.3685%2.38%-1.04%14/27 (-3)
Bandhan BSE Healthcare Index Fund Direct Plan-Growth

Growth
0.0004%0.06%0.06%88/102 (-4)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

SUVEN has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateFeb 17, 2021

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Feb 17, 2021

Cash Dividend

Ex DateEx DateFeb 14, 2019

Interim
Interim | Div/Share: ₹1.50

Dividend/Share

₹1.50

Ex DateEx Date

Feb 14, 2019

Cash Dividend

Ex DateEx DateFeb 6, 2018

Interim
Interim | Div/Share: ₹1.50

Dividend/Share

₹1.50

Ex DateEx Date

Feb 6, 2018

Cash Dividend

Ex DateEx DateFeb 8, 2017

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Feb 8, 2017

Cash Dividend

Ex DateEx DateMar 14, 2016

Special
Special | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Mar 14, 2016

News & Opinions
Earnings
Suven Life Sciences reports consolidated net loss of Rs 49.64 crore in the September 2024 quarter

Net Loss of Suven Life Sciences reported to Rs 49.64 crore in the quarter ended September 2024 as against net loss of Rs 12.68 crore during the previous quarter ended September 2023. Sales declined 16.01% to Rs 2.57 crore in the quarter ended September 2024 as against Rs 3.06 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2.573.06 -16 OPM %-2031.52-768.30 - PBDT-48.19-18.41 -162 PBT-49.64-20.14 -146 NP-49.64-12.68 -291 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Suven Life Sciences announces board meeting date

Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 29 October 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Live Market Update
Indices trade with major losses; media shares under pressure

The headline equity benchmarks traded with deep cuts in the mid-afternoon trade. The decline was driven by a global market sell-off amid concerns about a potential slowdown in U.S. economic growth. The Nifty traded below the 24,050 mark. Media shares extended losses for the third consecutive trading session. At 14:30 IST, the barometer index, the S&P BSE Sensex slumped 2,345.04 points or 2.90% to 78,636.91. The Nifty 50 index tanked 688.90 points or 2.79% to 24,028.80. The broader market underperformed the frontline indices. The S&P BSE Mid-Cap index dropped 3.76% and the S&P BSE Small-Cap index tumbled 4.19%. The market breadth was weak. On the BSE, 599 shares rose and 3,449 shares fell. A total of 104 shares were unchanged. The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, soared 43.38% to 20.53. Economy: The seasonally adjusted HSBC India Services Business Activity Index was at 60.3 in July, down only fractionally from 60.5 and above the neutral mark of 50.0 for the thirty-sixth straight month. The latest reading was more than six points higher than its long-run average and highlighted a substantial upturn in business activity. The HSBC India Composite Output Index posted 60.7 in July, down only fractionally from 60.9 in June and above the crucial 50.0 no-change mark for the thirty-sixth month running. Hence, the latest reading signaled a continuation of the strong growth momentum seen recently. As has been the case since February, the manufacturing industry led the upturn. Total new work rose sharply and at a pace that was considerably above its long-run average. Manufacturers experienced the stronger increase in new orders, despite a slowdown in its rate of expansion. Meanwhile, job creation remained solid across the two segments. Worryingly, charged inflation climbed to a near 11-and-a-halfyear high in July amid stronger increases at goods producers and service providers. Input cost inflation also ticked higher in July, but remained below its long-run average. Manufacturing firms reported stronger cost pressures than their services counterparts. India's foreign exchange reserves registered a decline of $3.471 billion, reaching $667.386 billion during the week ended July 26, according to the latest data from the Reserve Bank of India (RBI). Gold reserves fell by $2.297 billion to $57.695 billion during the week. Special drawing rights (SDRs) decreased by $5 million to $18.202 billion. India's reserve position with the International Monetary Fund (IMF) saw a modest increase of $2 million, reaching $4.612 billion in the reporting week. Buzzing Index: The Nifty Media index fell 4.35% to 2,008.95. The index slipped 6.54% in the three consecutive trading sessions. Nazara Technologies (down 6.56%), Dish TV India (down 6.26%), Saregama India (down 5.76%), Network 18 Media & Investments (down 5.57%), TV18 Broadcast (down 5.53%), Hathway Cable & Datacom (down 5.24%), Zee Entertainment Enterprises (down 4.56%), Tips Industries (down 4.28%), PVR Inox (down 4.07%) and Sun TV Network (down 0.64%) edged lower. Numbers to Track: The yield on India's 10-year benchmark federal rallied 1.16% to 6.980 as compared with previous close 6.977. In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 83.8425, compared with its close of 83.7250 during the previous trading session. MCX Gold futures for 5 October 2024 settlement shed 0.25% to Rs 70,154. The US Dollar index (DXY), which tracks the greenback's value against a basket of currencies, was down 0.73% to 102.45. The United States 10-year bond yield fell 1.11% to 3.745. In the commodities market, Brent crude for October 2024 settlement lost 80 cents or 0.1.04% to $76.01 a barrel. Stocks in Spotlight: Suven Life Sciences was locked in lower circuit of 5% after the company's consolidated net loss stood at Rs 28.04 crore in Q1 FY25 as compared with a net loss of Rs 24.09 crore in Q1 FY24. Net sales slipped 73.42% year on year (YoY) to Rs 1.01 crore in the quarter ended 30 June 2024. Devyani International rose 0.71%. The company has reported a consolidated net profit of Rs 22.4 crore in Q1 FY25 as against a net loss of Rs 1.6 crore in Q1 FY24. Revenue from operations increased by 44% year-over-year to Rs 1,221.9 crore in the June'24 quarter. VRL Logistics slipped 4.01% after the company's net profit decreased 60.41% to Rs 13.44 crore in Q1 FY25 as compared with Rs 33.95 crore posted in Q1 FY24. Revenue from operations grew by 7.86% to Rs 727.21 crore in Q1 FY25 as compared with Rs 674.22 crore recorded in the corresponding quarter previous year. Powered by Capital Market - Live

3 months agoCapital Market - Live

Suven Life Sciences reports consolidated net loss of Rs 28.04 crore in the June 2024 quarter

3 months agoBusiness Standard

Suven Life hits lower circuit as Q1 net loss widens to Rs 28 cr

3 months agoBusiness Standard
Earnings
Suven Life Sciences reports consolidated net loss of Rs 28.04 crore in the June 2024 quarter

Net Loss of Suven Life Sciences reported to Rs 28.04 crore in the quarter ended June 2024 as against net loss of Rs 24.09 crore during the previous quarter ended June 2023. Sales declined 73.42% to Rs 1.01 crore in the quarter ended June 2024 as against Rs 3.80 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1.013.80 -73 OPM %-3023.76-737.11 - PBDT-26.55-22.43 -18 PBT-28.04-24.09 -16 NP-28.04-24.09 -16 Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Suven Life hits lower circuit as Q1 net loss widens to Rs 28 cr

Consolidated net sales slipped 73.42% year on year (YoY) to Rs 1.01 crore in the quarter ended 30 June 2024. Total expenses shed 1.43% to Rs 33.05 crore in June 2024 quarter as against Rs 33.53 crore posted in same quarter last year. Employee benefits expense was Rs 4.69 crore (down 11.17% YoY) while finance costs stood at Rs 0.02 crore (down 60% YoY) during the period under review. R&D and Operational expenses rose marginally on YoY basis to Rs 24.92 crore in first quarter of FY25 compared with Rs 24.79 crore recorded in Q1 FY24. Suven Life Science is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Suven Life Sciences announces board meeting date

Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 5 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live

Angel One, Reliance Power, Motherson Wiring, Olectra Green — Buy, Sell Or Hold? AskProfit

10 months agoBloomberg Quint
Suven Life Sciences' Venkat Jasti Speaks On Weak Q4 Results & Suven Neuro Listing Plans | CNBC-TV18
1 year agoCNBC-TV18